Related Experiment Video
Updated: Jun 16, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
A Biomimetic Dual-Targeting Nano-APA-Editor Reprograms the 3'UTR Landscape for Tongue Squamous Cell Carcinoma Therapy
1State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Hubei Key Laboratory of Stomatology, Key Laboratory of Oral Biomedicine Ministry of Education, School & Hospital of Stomatology, Wuhan University, Wuhan, P. R. China.
Abstract:
Targeting post-transcriptional dysregulation of tumor suppressors represents a new frontier in cancer therapy. Here, we identify the alternative polyadenylation (APA) regulator NUDT21 as a pivotal therapeutic target in oral squamous cell carcinoma (OSCC). NUDT21 is highly upregulated, correlating strongly with poor survival and advanced clinical stage. We outline a pathogenic mechanism whereby NUDT21 drives this phenotype by forcing a network of tumor suppressor transcripts, notably PTEN, into translationally-repressed, long-3'UTR isoforms. To therapeutically "re-engineer" this APA switch, we design a "Nano-APA-editor." This platform features an HMSN core with an sgRNA-NUDT21 payload and a hierarchical targeting strategy: a cancer-educated dendritic cell (DC) membrane for biomimetic camouflage and homotypic affinity, "gated" by a TA-aptamer for final precision. This system enables potent and selective NUDT21 silencing, driving a shift toward short-3'UTR isoforms. Consequently, the Nano-APA-editor effectively reinstates PTEN and associated suppressors and inhibits multiple malignant phenotypes in vitro. In an orthotopic OSCC model, it demonstrates profound tumor regression, outperforming conventional chemotherapy (PTX) with excellent biocompatibility. In vivo analysis confirmed target engagement (NUDT21-down) and functional restoration (PTEN-, WEE1-, TGF-β-up). This work validates a "post-transcriptional re-engineering" strategy, executed by a logically designed nanoplatform, as a powerful and safe modality for precision gene therapy.
Insights
Researchers developed a novel nanoplatform, the Nano-APA-editor, to precisely target and silence NUDT21, a key regulator in oral cancer. This approach restores tumor suppressor function and effectively reduces oral squamous cell carcinoma growth.
Area of Science:
- Oncology
- Molecular Biology
- Nanomedicine
Background:
- Post-transcriptional regulation, specifically alternative polyadenylation (APA), is increasingly recognized as crucial in cancer development.
- Dysregulation of APA by NUDT21 promotes oral squamous cell carcinoma (OSCC) by creating translationally repressed, long 3'UTR isoforms of tumor suppressors like PTEN.
- NUDT21 upregulation correlates with poor prognosis and advanced stage in OSCC.
Purpose of the Study:
- To identify NUDT21 as a therapeutic target in OSCC.
- To develop a novel nanoplatform, the Nano-APA-editor, for precise NUDT21 targeting and silencing.
- To evaluate the therapeutic efficacy and safety of the Nano-APA-editor in OSCC models.
Main Methods:
- Design and synthesis of the Nano-APA-editor, incorporating an HMSN core, sgRNA-NUDT21 payload, and a dual-targeting strategy (DC membrane and TA-aptamer).
- In vitro assessment of NUDT21 silencing, 3'UTR isoform switching, PTEN restoration, and inhibition of malignant phenotypes.
- In vivo evaluation in an orthotopic OSCC model, comparing Nano-APA-editor efficacy and biocompatibility against paclitaxel (PTX).
- Confirmation of target engagement and functional restoration via in vivo molecular analysis.
Main Results:
- The Nano-APA-editor selectively silenced NUDT21, inducing a shift towards short 3'UTR isoforms and restoring PTEN and other tumor suppressors.
- In vitro studies demonstrated inhibition of malignant phenotypes.
- In vivo studies showed significant tumor regression in OSCC models, surpassing PTX efficacy with good biocompatibility.
- Confirmed NUDT21 downregulation and restoration of PTEN, WEE1, and TGF-β signaling in vivo.
Conclusions:
- NUDT21 is a critical therapeutic target in OSCC, driving malignant phenotypes through APA.
- The Nano-APA-editor represents a viable nanoplatform for precision gene therapy by re-engineering the APA switch.
- This 'post-transcriptional re-engineering' strategy offers a powerful and safe therapeutic modality for OSCC and potentially other cancers.
